Preclinical memory decline in cognitively normal apolipoprotein E–ε4 homozygotes

Objective: To determine, in a cross-sectional evaluation of nondemented individuals, if age-related memory decline is influenced by apolipoprotein E (apoE) genotype. Background: The apoE-4 allele is an important risk factor for AD. PET in cognitively normal apoE-4 carriers (mean age, 56 years) shows reduced cerebral metabolism suggestive of very early AD that precedes clinically evident memory loss or MRI-based hippocampal atrophy. Methods: Tests of immediate and delayed recall (primary outcome measures) and other neuropsychological measures (secondary outcome measures) were given to three genetically defined groups of cognitively normal individuals (age, 49 to 69 years) including apoE-4 homozygotes (n = 25), apoE-4 heterozygotes (n = 25, all ε3/4), and apoE-4 noncarriers (n = 50). Groups were matched for age, gender, and educational background. Cross-sectional comparisons between the genetic subgroups of the relationship between age and test score were performed for each neuropsychological measure. Results: There were no intergroup differences in mean scores on any neuropsychological measure, but tests sensitive to immediate and delayed recall showed a significant negative correlation with age in the apoE-4 homozygote group relative to the noncarrier group. Conclusion: Consistent with previous neuropsychological studies of early AD, this cross-sectional study suggests that age-related memory decline occurs earlier in cognitively healthy apoE-4 homozygotes than in apoE-4 heterozygotes and noncarriers, and precedes clinically detectable AD.

[1]  M N Rossor,et al.  Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. , 1998, Brain : a journal of neurology.

[2]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[3]  Daniel Bandy,et al.  Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease , 1998, Annals of neurology.

[4]  S. Ferris,et al.  Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work group , 1986 .

[5]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[6]  B T Hyman,et al.  Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.

[7]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[8]  A. Kurz,et al.  Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease , 1996, Neurology.

[9]  A. Baddeley,et al.  The Quarterly Journal of Experimental Psychology Section a Human Experimental Psychology Dementia and Working Memory Dementia and Working Memory , 2022 .

[10]  B. Winblad,et al.  Apolipoprotein ϵ4 allele and disease progression in patients with late-onset Alzheimer's disease , 1995, Neuroscience Letters.

[11]  D. Carmelli,et al.  Lower Cognitive Performance in Normal Older Adult Male Twins Carrying the Apolipoprotein E ε4 Allele , 1994 .

[12]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[13]  N Butters,et al.  Episodic memory changes are associated with the APOE- epsilon 4 allele in nondemented older adults , 1995, Neurology.

[14]  J. Lindeboom,et al.  Association between apolipoprotein E ε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia , 1998 .

[15]  J T Becker,et al.  Working memory and secondary memory deficits in Alzheimer's disease. , 1988, Journal of clinical and experimental neuropsychology.

[16]  M. D’Esposito,et al.  The neural basis of the central executive system of working memory , 1995, Nature.

[17]  R. Morris,et al.  Short-term forgetting in senile dementia of the Alzheimer's type , 1986 .

[18]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[19]  P. S. St George-Hyslop,et al.  Prediction of probable Alzheimer's disease in memory-impaired patients , 1996, Neurology.

[20]  S. Corkin,et al.  Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease , 1996, Neurology.

[21]  J E Smialek,et al.  Neuropathology of preclinical and clinical lateonset Alzheimer's disease , 1998, Annals of neurology.

[22]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[23]  R. Brookmeyer,et al.  Apolipoprotein E genotype and rate of decline in probabole Alzheimer's disease , 1996 .

[24]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[25]  Jonathan D. Brodie,et al.  Positron emission tomography studies of normal aging: A replication of PET III and 18-FDG using PET VI and 11-CDG , 1987, Neurobiology of Aging.

[26]  L L Light,et al.  Working-memory capacity, age, and memory for discourse. , 1985, Journal of gerontology.

[27]  A. Baddeley,et al.  Amnesia and the distinction between long- and short-term memory. , 1970 .

[28]  E. Corder,et al.  Apolipoprotein E Genotype and Rate of Decline in Probable Alzheimer's Disease , 1996 .

[29]  K. Marder,et al.  Neuropsychological detection and characterization of preclinical Alzheimer's disease , 1995, Neurology.